>
COMMANDS Global: GP Symbol: IBM FA
↑↓ Navigate Enter Open Esc Close ` Toggle

Summary

25.62 -0.39 (-1.50%) 10/02/2026
Stoke Therapeutics, Inc. (STOK)
Performance
Historical returns
1D
-1.50%
1W
0.47%
1M
-16.00%
3M
-21.65%
6M
-21.75%
1Y
3.22%
5Y
-0.97%
Snapshot
Key statistics
Close
25.62
Change
-0.39
Change %
-1.50%
Open
26.46
Day Range
25.45 – 26.46
Volume
582,392
Avg Vol (20d)
819,119
Rel Vol
0.71x
52W Range
20.32 - 40.22
vs 52W High
-36.30%
vs 52W Low
26.08%
Gap
-0.05
Market Cap
USD 1.65B
Beta
1.14
Price Chart
Advanced chartCompare
Last 730 data points are shown. To view all data, Create a free account
Bull vs Bear
5 bullish · 7 bearish points
Bullish view
  • Consensus looks for 238.4% revenue growth in 2030 to $624.00M.
  • Revenue in the same quarter came in $4.44M ahead of consensus.
  • Trades at just 11.9× the 2030 consensus EPS of $2.15.
  • Sits 76.9% below the average analyst target of $45.33 across 9 firms.
  • 7 of 8 covering analysts rate the shares a buy.
Bearish view
  • Operating margin compressed to -701.7% in the Jun 2026 quarter from -197.6% a year earlier.
  • Gross margin slipped to 87.8% from 100.0% a year ago.
  • Revenue fell 32.5% year on year in the Jun 2026 quarter.
  • The Aug 2026 quarter missed on EPS by $0.14 (17.0% below consensus).
  • Trades 19.1% below its 200-day average, a downtrend still intact.
  • Still 33.2% below its 52-week high of $38.35.
  • Lagged the S&P 500 by 23.4% over the last quarter (-21.0% against +2.4%).
Both sides are generated from reported financials, consensus estimates, analyst targets and the price series — not from opinion.
Notable Price Movement
Historical returns
Oct 2
2026
$25.62 1.50%Latest
Stoke Therapeutics fell 1.50% to $25.62. This was largely stock-specific: the S&P 500 gained 0.74% while Healthcare peers (XLV) fell 0.01% that session, leaving about 1.5 points of the move unexplained by its sector. Shares opened with a 1.73% gap up and reversed through the session and closed near the session low (17% of the day's range). The move left the stock 33.2% below its 52-week high.
Sep 24
2026
$25.29 3.14%
Stoke Therapeutics fell 3.14% to $25.29, on 1.6× average volume. This was largely stock-specific: the S&P 500 fell 0.08% while Healthcare peers (XLV) rose 0.63% that session, leaving about 3.0 points of the move unexplained by the market after adjusting for a 1.14 beta.
Sep 23
2026
$26.11 10.58%
Stoke Therapeutics fell 10.58% to $26.11, its biggest one-day drop in 11 months and a 4.1σ move against its 60-day volatility, on 1.6× average volume. This was largely stock-specific: the S&P 500 fell 0.72% while Healthcare peers (XLV) fell 0.64% that session, leaving about 9.8 points of the move unexplained by the market after adjusting for a 1.14 beta. Shares closed near the session low (2% of the day's range). The move erased $204.0M of market value.
Sep 22
2026
$29.20 4.10%
Stoke Therapeutics rose 4.10% to $29.20, its biggest one-day gain in 2 months and a 1.6σ move against its 60-day volatility, though on light volume (0.7× the 20-day average). This was largely stock-specific: the S&P 500 fell 0.02% while Healthcare peers (XLV) rose 0.52% that session, leaving about 3.6 points of the move unexplained by its sector. Shares opened with a 1.07% gap up and closed near the session high (83% of the day's range).
Sep 17
2026
$28.93 3.65%
Stoke Therapeutics rose 3.65% to $28.93, its biggest one-day gain in 1 month. Roughly 2.1 points were stock-specific — the S&P 500 gained 1.39% while Healthcare peers (XLV) rose 0.62% alongside it. Shares opened with a 3.26% gap up.
Sep 15
2026
$28.15 4.90%
Stoke Therapeutics fell 4.90% to $28.15, its biggest one-day drop in 3 weeks and a 2.0σ move against its 60-day volatility, on 1.4× average volume. This was largely stock-specific: the S&P 500 fell 0.46% while Healthcare peers (XLV) fell 0.05% that session, leaving about 4.4 points of the move unexplained by the market after adjusting for a 1.14 beta. Shares closed near the session low (19% of the day's range).
Computed from adjusted closes over the last 22 sessions; attribution vs SPY and XLV.
Price Performance
All periods
PeriodPeriod LowPeriod HighPerformance
1-Month24.21 +5.85%
on 09/28/26
Open 30.50
32.12 -20.24%
on 09/02/26
-4.88 (-16.00%)
since 09/02/26
3-Month24.21 +5.85%
on 09/28/26
Open 32.43
33.94 -24.51%
on 08/25/26
-6.81 (-21.00%)
since 07/06/26
6-Month24.21 +5.85%
on 09/28/26
Open 32.74
37.35 -31.41%
on 04/17/26
-7.12 (-21.75%)
since 04/02/26
YTD24.21 +5.85%
on 09/28/26
Open 30.90
40.22 -36.30%
on 03/10/26
-5.28 (-17.09%)
since 01/02/26
52-Week20.32 +26.08%
on 11/05/25
Open 23.59
40.22 -36.30%
on 03/10/26
+2.03 (+8.61%)
since 10/01/25
5-Year3.35 +664.78%
on 10/27/23
Open 26.00
40.22 -36.30%
on 03/10/26
-0.38 (-1.46%)
since 09/24/21
New Highs
Historical highs
5-Day
3×
-1.50% from peak
1-Month
1×
-14.74% from peak
3-Month
2×
-23.43% from peak
6-Month
5×
-31.26% from peak
YTD
7×
-33.19% from peak
52-Week
11×
-33.19% from peak
2-Year
34×
-33.19% from peak
3-Year
47×
-33.19% from peak
5-Year
10×
-33.19% from peak
10-Year
n/a
not enough history
Financial SnapshotFY 2025
Full financials
Revenue
USD 184.42M
+404.5% YoY
Net Income
-USD 6.89M
-92.3% YoY
EPS
-0.12
-92.7% YoY
Gross Margin
100.0%
Operating Margin
-11.2%
Net Margin
-3.7%
EBITDA
-USD 5.12M
Free Cash Flow
USD 44.92M
24.4% margin
ROE
-2.0%
ROA
-1.6%
Debt / Equity
0.01x
net debt -USD 81.21M
Cash & Equiv.
USD 84.22M
News
All news
10/05 07:00 ET · businesswire.com
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential...
09/28 03:25 ET · defenseworld.net
Stoke Therapeutics, Inc. $STOK Shares Newly Acquired by Corient Private Wealth LP
Corient Private Wealth LP purchased a new stake in Stoke Therapeutics, Inc. (NASDAQ: STOK) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 30,823 shares of the company's stock, valued at approximately $1,009,000. Other institutional investors...
09/23 16:01 ET · businesswire.com
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential...
09/18 04:34 ET · defenseworld.net
Squarepoint Ops LLC Acquires Shares of 29,310 Stoke Therapeutics, Inc. $STOK
Squarepoint Ops LLC acquired a new position in Stoke Therapeutics, Inc. (NASDAQ: STOK) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 29,310 shares of the company's stock, valued at approximately $959,000. A number...
09/16 16:01 ET · businesswire.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential...
09/03 20:00 ET · gurufocus.com
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
[url="]Stoke Therapeutics, Inc.[/url] (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with
09/03 19:30 ET · businesswire.com
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th...
09/02 08:00 ET · businesswire.com
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential...

Market News ×
Loading news…